Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.149
Sell
RSI(14)
43.061
Neutral
STOCH(KDJ)(9,3,3)
33.992
Neutral
ATR(14)
0.512
Low Volatility
CCI(14)
-54.769
Neutral
Williams %R
78.924
Sell
TRIX(12,20)
-0.379
Sell
StochRSI(14)
78.469
Neutral
Prothena Corporation PLC
PRTA9.540USD
-0.150-1.55%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
513.54MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Prothena Corporation PLC
Currency: USD Updated: 2025-12-26Key Insights
Prothena Corporation PLC's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 131/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 20.33.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prothena Corporation PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Hold
Current Rating
20.333
Target Price
+89.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prothena Corporation PLC Highlights
StrengthsRisks
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 150.73% year-on-year.
Overvalued
The company’s latest PE is -1.83, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.85M shares, decreasing 26.64% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 3.67K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Prothena Corporation PLC is 6.59, ranking 247/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.42M, representing a year-over-year increase of 148.97%, while its net profit experienced a year-over-year increase of 38.07%.
Score
Financials
9.42
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.78
Operational Efficiency
2.83
Growth Potential
5.83
Shareholder Returns
7.07
Prothena Corporation PLC's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Prothena Corporation PLC is 7.12, ranking 178/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.83, which is -41.10% below the recent high of -1.08 and -2040.22% above the recent low of -39.18.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 131/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Prothena Corporation PLC is 6.86, ranking 328/404 in the Biotechnology & Medical Research industry. The average price target for Prothena Corporation PLC is 18.50, with a high of 36.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
20.333
Target Price
+89.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Prothena Corporation PLC
PRTA
7
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Prothena Corporation PLC is 4.52, ranking 360/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.05 and the support level at 8.55, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.522
Buy
MA10
9.650
Sell
MA20
10.126
Sell
MA50
10.230
Sell
MA100
9.507
Buy
MA200
8.757
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Prothena Corporation PLC is 7.00, ranking 85/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 77.74%, representing a quarter-over-quarter decrease of 18.47%. The largest institutional shareholder is The Vanguard, holding a total of 2.05M shares, representing 3.81% of shares outstanding, with 62.60% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
Scully (William P)
Fennell (Todd W.)
BlackRock Institutional Trust Company, N.A.
Armistice Capital LLC
Adar1 Capital Management LLC
Palo Alto Investors LP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Prothena Corporation PLC is 6.19, ranking 34/404 in the Biotechnology & Medical Research industry. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.11
VaR
+6.56%
240-Day Maximum Drawdown
+71.45%
240-Day Volatility
+77.63%
Return
Best Daily Return
60 days
+7.92%
120 days
+12.66%
5 years
+87.52%
Worst Daily Return
60 days
-6.18%
120 days
-6.18%
5 years
-30.40%
Sharpe Ratio
60 days
+0.04
120 days
+2.03
5 years
+0.12
Risk Assessment
Maximum Drawdown
240 days
+71.45%
3 years
+94.17%
5 years
+94.19%
Return-to-Drawdown Ratio
240 days
-0.38
3 years
-0.29
5 years
-0.13
Skewness
240 days
-1.59
3 years
+0.68
5 years
+4.67
Volatility
Realised Volatility
240 days
+77.63%
5 years
+76.56%
Standardised True Range
240 days
+6.32%
5 years
+21.89%
Downside Risk-Adjusted Return
120 days
+425.70%
240 days
+425.70%
Maximum Daily Upside Volatility
60 days
+40.54%
Maximum Daily Downside Volatility
60 days
+28.43%
Liquidity
Average Turnover Rate
60 days
+2.36%
120 days
+2.45%
5 years
--
Turnover Deviation
20 days
+49.91%
60 days
+62.31%
120 days
+68.63%
Peer Comparison
Biotechnology & Medical Research
Prothena Corporation PLC
PRTA
6.31 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Prothena Corporation PLC?
The TradingKey Stock Score provides a comprehensive assessment of Prothena Corporation PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Prothena Corporation PLC’s performance and outlook.
How do we generate the financial health score of Prothena Corporation PLC?
To generate the financial health score of Prothena Corporation PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Prothena Corporation PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Prothena Corporation PLC.
How do we generate the company valuation score of Prothena Corporation PLC?
To generate the company valuation score of Prothena Corporation PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Prothena Corporation PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Prothena Corporation PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Prothena Corporation PLC.
How do we generate the earnings forecast score of Prothena Corporation PLC?
To calculate the earnings forecast score of Prothena Corporation PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Prothena Corporation PLC’s future.
How do we generate the price momentum score of Prothena Corporation PLC?
When generating the price momentum score for Prothena Corporation PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Prothena Corporation PLC’s prices. A higher score indicates a more stable short-term price trend for Prothena Corporation PLC.
How do we generate the institutional confidence score of Prothena Corporation PLC?
To generate the institutional confidence score of Prothena Corporation PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Prothena Corporation PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Prothena Corporation PLC.
How do we generate the risk management score of Prothena Corporation PLC?
To assess the risk management score of Prothena Corporation PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Prothena Corporation PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Prothena Corporation PLC.
